New broad-spectrum vaccine to prevent cervical cancer induces strong responses in animals

May 26, 2009

Mice and rabbits immunized with a multimeric-L2 protein vaccine had robust antibody responses and were protected from infection when exposed to human papillomavirus (HPV) type 16 four months after vaccination, according to a new study published in the May 26 online issue of the Journal of the National Cancer Institute.

Current HPV L1-based vaccines are almost 100% protective against infection by the two HPV types that are responsible for 70% of all cases world wide. However, the existing vaccines provide limited protection against the other HPV types that cause cancer. With that limitation in mind, Richard Roden, Ph.D., of the Johns Hopkins University in Baltimore, and colleagues have been working on an alternate that is based on the HPV minor capsid protein L2, which is highly conserved between HPV types. Previous experiments showed that the L2 protein induced only a weak antibody response in animals.

In the current study, Roden and colleagues linked together a short segment of the L2 protein from several HPV types to generate a single multimeric L2 fusion protein. They tested the ability of this multimeric-L2 protein to induce antibody responses in animals and its ability to protect them from subsequent infection with HPV type 16.

Mice immunized with the multimeric L2 vaccine developed robust antibody responses against all of the HPV types tested, although the antibody titer was still lower than the type-restricted responses following vaccination with an existing HPV L1-based vaccine. When a multimeric L2 vaccine was delivered with a potent adjuvant to stimulate the , such as alum, the vaccinated animals were able to resist infection by HPV16.

"Clinical studies are warranted to assess the safety and immunogenicity of multitype L2 vaccines in alum and other adjuvant formulations," the authors write. "If an L2 vaccine were proven effective in people, its simpler manufacturing process could make the local production of such a vaccine highly feasible, which might achieve the goal of producing it at sustainable prices in emerging countries and lead to its widespread implementation in the developing world."

In an accompanying editorial, F. Xavier Bosch, M.D., Ph.D., of the Catalan Institute of Oncology, in Barcelona, Spain, reviews the strengths of the current HPV vaccines but notes that they are too expensive to be used in much of the world and do not protect against enough HPV types. A broad-spectrum vaccine, such as the one being developed by Roden and colleagues, could solve those problems. The new data represent a meaningful step forward, Bosch says.

"The results open the door to a novel family of second generation HPV vaccines with significant potential value in the public health horizon," the editorialist writes. "As soon as appropriate, Phase 1 trials in humans should be initiated."

The clinical evaluation of new products, however, will likely take years. During this time, the currently available vaccines should be used as widely as possible, according to the editorialists.

More information:

Article: Jagu et al. Concatenated Multitype L2 as Candidate Prophylactic Pan-Human Papillomavirus Vaccines. J Natl Cancer Inst 2009, 101: 782-792.
Editorial: Bosch, F.X. Broad-Spectrum Vaccines: New Horizons but One Step at a Time. J Natl Cancer Inst 2009, 101: 771-773

Source: (news : web)

Explore further: DNA alternative to Pap smear sparks medical debate (Update)

add to favorites email to friend print save as pdf

Related Stories

New HPV vaccine under study

Nov 19, 2007

A new vaccine against nine of the most harmful strains of human papillomavirus is under study at the Medical College of Georgia.

Study explores attitudes and beliefs about HPV

Mar 01, 2007

The most common sexually transmitted virus in the US is genital human papillomavirus (HPV) infection, with 20 million Americans currently infected and another 6.2 million becoming infected each year. Although HPV causes serious ...

Tattooing improves response to DNA vaccine

Feb 07, 2008

A tattoo can be more than just a fashion statement – it has potential medical value, according to an article published in the online open access journal, Genetic Vaccines and Therapy.

Recommended for you

DNA alternative to Pap smear sparks medical debate (Update)

15 hours ago

A high-tech screening tool for cervical cancer is facing pushback from more than a dozen American patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: ...

User comments : 0

More news stories

ESO image: A study in scarlet

This new image from ESO's La Silla Observatory in Chile reveals a cloud of hydrogen called Gum 41. In the middle of this little-known nebula, brilliant hot young stars are giving off energetic radiation that ...

First direct observations of excitons in motion achieved

A quasiparticle called an exciton—responsible for the transfer of energy within devices such as solar cells, LEDs, and semiconductor circuits—has been understood theoretically for decades. But exciton movement within ...

Warm US West, cold East: A 4,000-year pattern

Last winter's curvy jet stream pattern brought mild temperatures to western North America and harsh cold to the East. A University of Utah-led study shows that pattern became more pronounced 4,000 years ago, ...

Patent talk: Google sharpens contact lens vision

(Phys.org) —A report from Patent Bolt brings us one step closer to what Google may have in mind in developing smart contact lenses. According to the discussion Google is interested in the concept of contact ...